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Abstract
A large genomic deletion in human cardiac ryanodine receptor (RYR2) gene has been detected in a number of unrelated
families with various clinical phenotypes, including catecholaminergic polymorphic ventricular tachycardia (CPVT). This
genomic deletion results in an in-frame deletion of exon-3 (Ex3-del). To understand the underlying disease mechanism of
the RyR2 Ex3-del mutation, we generated a mouse model in which the RyR2 exon-3 sequence plus 15-bp intron sequences
flanking exon-3 were deleted. Heterozygous Ex3-del mice (Ex3-del+/2) survived, but no homozygous Ex3-del mice were
born. Unexpectedly, the Ex3-del+/2 mice are not susceptible to CPVT. Ex3-del+/2 cardiomyocytes exhibited similar
amplitude but altered dynamics of depolarization-induced Ca2+ transients compared to wild type (WT) cells.
Immunoblotting analysis revealed markedly reduced expression of RyR2 protein in the Ex3-del+/2 mutant heart, indicating
that Ex3-del has a major impact on RyR2 protein expression in mice. Cardiac specific, conditional knockout of the WT RyR2
allele in Ex3-del+/2 mice led to bradycardia and death. Thus, the absence of CPVT and other phenotypes in Ex3-del+/2 mice
may be attributable to the predominant expression of the WT RyR2 allele as a result of the markedly reduced expression of
the Ex3-del mutant allele. The effect of Ex3-del on RyR2 protein expression is discussed in relation to the phenotypic
variability in individuals with the RyR2 exon-3 deletion.
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Introduction
The cardiac Ca2+ release channel (ryanodine receptor type 2,
RyR2) plays an essential role in excitation-contraction (EC)
coupling and sarcoplasmic reticulum Ca2+ handling in the heart
[1]. RyR2 is also a key player in the pathogenesis of cardiac
arrhythmias and cardiomyopathies [2]. To date, more than 150
mutations in RyR2 have been associated with different forms of
cardiac arrhythmias, including catecholaminergic polymorphic
ventricular tachycardia (CPVT), catecholaminergic idiopathic
ventricular fibrillation, and atrial fibrillation [2–5]. Most patients
with RyR2 mutations exhibit structurally normal hearts.
However, some RyR2 mutations have been linked to cardio-
myopathies as well as cardiac arrhythmias [6–11]. For instance,
a large genomic deletion (1.1–3.6 kb) in the RYR2 gene that
covers exon-3 was identified in a number of unrelated families
[11–14]. Individuals with this exon-3 deletion display a wide
spectrum of clinical phenotypes, including CPVT, sinoatrial
node dysfunction, bradycardia, atrial fibrillation, AV block,
dilated cardiomyopathy, and left ventricular non-compaction.
The deletion of exon-3 results in an in-frame deletion of 35
amino acid residues (Asn57-Gly91) in the NH2-terminal region of
the RyR2 channel that is believed to be important for channel
function [15–18]. Interestingly, the missing structural element due
to exon-3 deletion can be rescued by a b-strand switching [16,17].
As a result, the exon-3 deletion does not grossly affect the overall
folding of the NH2-terminal domain of RyR2. Consistent with
these observations, functional studies in HEK293 cells revealed
that the exon-3 deleted RyR2 mutant remained functional, but
displayed altered properties of Ca2+ release activation and
termination [18].
Although the structural impact of the exon-3 deletion and its
effect on spontaneous Ca2+ release in the heterologous HEK293
cells have been well characterized, the mechanisms by which
the exon-3 deletion in RyR2 causes cardiac arrhythmias and
cardiomyopathy are unknown. Genetically engineered mouse
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models harboring disease-associated mutations have been widely
used for studying disease mechanisms. Indeed, a number of
knock-in mice expressing RyR2 mutations linked to CPVT have
been generated and characterized [19–26]. These RyR2 mutant
mice have provided important insights into how RyR2
mutations cause CPVT. However, in contrast to CPVT-
associated RyR2 mutations, there are few models that express
cardiomyopathy-associated RyR2 mutations. In an attempt to
understand the disease mechanism underlying RyR2-associated
cardiomyopathies, in the present study, we generated a mouse
model in which the entire exon-3 and part of the introns 2 and
4 were deleted using the knock-in approach. Unexpectedly, we
found that this deletion has a dramatic impact on the
expression of the mouse RyR2 protein. The observation that
the exon-3 deletion alters the expression of RyR2 may provide
some clues to the various clinical phenotypes and variable
severities of patients with the RyR2 exon-3 deletion [11–14].
Materials and Methods
Generation of a mouse model harboring the RyR2 exon-3
deletion
A genomic DNA phage clone containing part of the mouse
cardiac ryanodine receptor gene was isolated from the lambda
mouse 129-SV/J genomic DNA library (Stratagene) and used to
construct the RyR2 exon-3 deletion (Ex3-del) knock-in (KI)
targeting vector. This genomic DNA fragment (about 15 kb)
was released from the lambda vector by NotI, and subcloned
into pBluescript to form the RyR2 genomic DNA plasmid.
PCR-based site-directed mutagenesis was performed to generate
a 660 bp DNA fragment containing the Ex3-del mutation using
this RyR2 genomic DNA plasmid as a template. An XhoI site
was created in the 59 and a BamH I site in the 39 in this DNA
fragment. The modified XhoI-BamHI fragment was then
subcloned into the targeting vector that contains a neomycin
selection cassette flanked by FRT sites using BamH I and XhoI.
The 2186 bp HindIII-HindIII and the 5994 bp AflII-AflII
genomic DNA fragments were isolated from the RyR2 genomic
DNA plasmid and inserted into the targeting vector to form the
59 arm via the HindIII sites and the 39 arm via the AflII sites,
respectively. The DNA sequences of all PCR fragments used for
constructing the targeting vector were confirmed by DNA
sequencing. The targeting vector was linearized with NotI and
subsequently electroporated into R1 embryonic stem (ES) cells.
G418-resistant ES clones were screened for homologous
recombination by Southern blotting using an external probe.
Briefly, genomic DNA was extracted from G418-resistant ES
cell clones. ES cell DNA was digested using BglII, separated on
a 0.8% (wt/vol) agarose gel, and subsequently blotted onto a
nitrocellulose membrane. A DNA probe (,700 bp) was
generated by PCR from mouse genomic DNA using the
specific primers, forward: 59-TGCCTTGTCGTCAAT-
TAAGCTGT-39; and reverse: 59-TACATGTGTG-
CAGTTGCCCATA-39. The PCR product was subsequently
radiolabeled using [32P]dCTP by random priming (Invitrogen).
DNA blots were hybridized with the radiolabeled probe and
visualized by autoradiography. Eight positive homologous
recombinants were detected out of 780 ES cell clones, two of
which were microinjected into blastocysts from C57BL/6J mice
to generate male chimeras. Male chimeras were bred with
female 129sve mice to generate germline transmitted heterozy-
gous Ex3-del neo knock-in mice. RyR2 Ex3-del neo male mice
were bred with female mice that express Flp recombinase to
remove the selectable marker (the neomycin resistant gene, neo).
The genotypes from F1 generation without neo were deter-
mined by PCR using DNA from tail biopsy specimens using the
DNeasy Tissue Kit from Qiagen and the DNA primers,
forward: 59-CACAGACACACAGTAAGGCATTAC-39; re-
verse: 59-GTATGTCTTTCAGACATCCTAAGC -39.
All animal studies were approved by the Institutional Animal
Care and Use Committees at the University of Calgary, and
performed in accordance with NIH guidelines. RyR2 WT and
mutant mice (1.5–9 months of age) were used for all experiments.
Confirmation of exon-3 deletion at the mRNA level using
RT-PCR
Total RNA was isolated from about 100 mg of heart tissues
from RyR2 exon-3 deletion mutant mice or RyR2 wild type
mice using the RNA isolation kit (Invitrogen) according to the
manufacturer’s instructions. First-strand cDNA was synthesized
from ,5 mg of total RNA using Superscript II RNase H reverse
transcriptase (Invitrogen) with gene-specific primer (59-
ATAGCCTTGGGCTGCTTCACTTCC) at 50uC. Amplifica-
tion of cDNA fragments by polymerase chain reaction (PCR)
was performed in a 50 ml mixture that contains 1 ml cDNA,
10 ml 56 PCR buffer, 0.5 mM of each forward or reverse gene-
specific primer (Forward primer: 59-TGATGCGGGC-
GAAGGCGAGGAT; Reverse primer:59-GAAGGCAGCATC-
CACATGCCAGCT), 200 mM dNTP, and 0.01 U Q5 High-
Fidelity DNApolymerase (New England Biolab). PCR was
performed in a thermocycler with an initial denaturation at
98uC for 30 seconds, followed by 30 cycles (10 s at 98uC, 15 s
at 68uC, and 30s at 72uC) of amplification, and a final cycle of
2 min at 72uC. PCR products were separated by 1.8% agarose
gel electrophoresis, and desired DNA fragments were purified
using QIAGEN DNA Extraction kit and cloned into pBluescript
vector. Plasmid DNA was isolated using QIAGEN Plasmid
Purification kit. Insert-positive clones were identified by
restriction enzyme digestion (EcoRI and HindIII), and their
sequences were determined by DNA sequencing.
Generation of inducible, cardiac specific, conditional
RyR2 knockout mice containing RyR2 exon-3 deletion
The conditional RyR2 knockout (KO) mouse model (RyR2-
floxed mice) was generated as described previously [27–29].
These RyR2-floxed mice were crossed with the myosin heavy
chain (MHC)-mer-Cre-mer mice that express the tamoxifen-
inducible, MHC promoter-controlled Cre-recombinase [30].
This breeding produced tamoxifen-inducible, cardiac-specific,
heterozygous RyR2 conditional KO mice (iRyR2wt/flox), which
were used to generate tamoxifen-inducible, cardiac-specific,
homozygous RyR2 conditional KO mice (iRyR2flox/flox). These
iRyR2flox/flox mice were used to conditionally and specifically
diminish the expression of the WT RyR2 allele. To do this, we
bred the iRyR2flox/flox mice with the RyR2 Ex3-del+/2 mutant
mice to generate the iRyR2flox/Ex3-del mice. For induction of
knockout of the WT RyR2 allele, tamoxifen (sigma, 75 mg/kg/
day) was injected (intraperitoneal, i.p.) into iRyR2flox/Ex3-del and
iRyR2flox/flox mice (1.5–2 months) for 3 consecutive days. The
mice were used for stress tests and immunoblotting analysis
,12 days post tamoxifen treatment.
ECG recordings
RyR2 Ex3-del+/2 mutant mice and their WT littermates,
iRyR2flox/Ex3-del, and iRyR2flox/flox mice were assessed for their
susceptibility to stress-induced ventricular tachyarrhythmias using
ECG recording [24]. Briefly, mice were lightly anesthetized with
Exon-3 Deletion Reduces RyR2 Expression in Mice
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isoflurane vapor (0.5–1%) and 95% O2. Anesthetized mice were
placed on a heating pad (27uC) and needle electrodes were
inserted subcutaneously into the right upper limb and left lower
abdomen for ECG recording (BIOPAC MP System, Goleta, CA).
The animals9 ECG was continuously monitored under anesthesia
until the heart rate became stabilized. Baseline ECG was recorded
for 5–10 minutes. For induction of ventricular arrhythmias, the
mice were subjected to intraperitoneal injection of a mixture of
epinephrine (1.6 mg/kg) and caffeine (120 mg/kg). ECG was
continuously recorded for 30 minutes after the injection of
epinephrine and caffeine.
Western blotting
Mouse hearts were crushed by a Wollenberger clamp pre-
cooled in liquid nitrogen. The crushed heart tissues were stored
at 280uC until use. Frozen heart tissues were pulverized in
liquid nitrogen and homogenized immediately in 6 volumes of
homogenizing buffer containing 30 mM KH2PO4 (pH 7.0),
40 mM NaF, 5 mM EDTA, 300 mM sucrose, 4 mM leupeptin,
1 mM benzamidine, 100 mM PMSF, and 0.5 mM DTT,
aliquoted, frozen with liquid nitrogen and stored at 280uC
until use. Aliquots of homogenates were solubilized in a final
500 ml of solubilizing buffer containing 50 mM Tris-HCl
(pH 7.4) plus 3% SDS for 1 h at room temperature and then
incubated at 55uC for 10 min. The insoluble materials were
removed by centrifugation at 12,0006g for 10 min [31]. The
protein concentration of the supernatant was determined using
a BioRad detergent-compatible protein assay kit. Solubilized
proteins (15–20 mg) were used for SDS-PAGE [32]. RyR2
proteins resolved in 6% SDS-PAGE were transferred to
nitrocellulose membranes at 45 V for 18–20 h at 4uC in the
presence of 0.01% SDS according to the method of Towbin
et al [33]. For the detection of b-actin, proteins were separated
in 15% SDS-PAGE and transferred at 110 V for 1 h at 4uC.
The nitrocellulose membranes containing the transferred pro-
teins were blocked for 30 min with phosphate buffered saline
(PBS) containing 0.5% Tween-20 and 5% skim milk powder.
The blocked membrane was incubated with anti-RyR2 or anti-
b-actin antibodies, and washed with PBS containing 0.5%
Tween-20 for three times with shaking, each time for 5 min.
The membrane was then incubated with the secondary anti-
mouse or anti-rabbit IgG (H&L) antibodies conjugated to
horseradish peroxidase (1:20,000) for 30 min. After washing
with PBS containing 0.5% Tween-20 for three times, the bound
antibodies were detected using an enhanced chemiluminescence
kit from Pierce. The intensity of each band was determined
from its intensity profile obtained by ImageQuant LAS 4000
(GE Healthcare Life Sciences), analyzed by using the Image-J
software, and normalized to that of b-actin.
Single cell Ca2+ imaging of isolated ventricular myocytes
Ventricular myocytes were isolated using retrograde aortic
perfusion as described previously [34]. Isolated cells were kept
at room temperature in Krebs-Ringers-HEPES (KRH) buffer (in
mM: 125 NaCl, 12.5 KCl, 25 HEPES, 6 glucose, and 1.2
MgCl2, pH 7.4) containing 20 mM taurine, 20 mM 2,3-
butanedione monoxime (BDM), 5 mg/ml albumin, and 1 mM
free Ca2+ until use. Freshly isolated mouse ventricular myocytes
were added to glass coverslips pre-coated with 50 mg/ml
laminin, and loaded with 5 mM Rhod-2, AM (Molecular
Probes, USA) in KRH buffer containing 1 mM Ca2+ for
20 min at room temperature as described previously [35]. The
glass coverslip pre-mounted to a recording chamber was then
placed onto an inverted microscope (Nikon ECLIPSE Ti)
equipped with a Nikon CFI Plan Apo VC 60xWI objective.
Then Rhod-2 loaded cells were perfused with KRH buffer
containing 2 mM extracellular Ca2+ and 5 mM blebbistatin. The
cells were paced by field stimulation using the S88X electric
stimulator (Grass, USA) at 3 Hz. Confocal line-scanning (512
pixels and 1.9 ms per line) were performed along the
longitudinal axis of cells for 10 seconds using the Nikon A1R
confocal system. The Rhod-2 loaded myocytes were excited
using the 561 nm diode laser and the fluorescence emission at
570–620 nm was recorded. The line-scan images were processed
and analyzed with the NIS-Elements AR 4.0.
Statistical analysis
All values shown are mean 6 SEM unless indicated otherwise.
To test for differences between groups, we used unpaired Student’s
t tests (2-tailed). A P value ,0.05 was considered to be statistically
significant.
Results
Generation of a mouse model expressing the RyR2 exon-
3 deletion mutant
Naturally occurring deletion of exon-3 (Ex3-del) encoding
residues Asn57-Gly91 in the NH2-terminal region of the RyR2
channel has been linked to various cardiac abnormalities in
humans, but their causal mechanisms are unknown [11–14]. To
determine the physiological consequence of this deletion, we
generated a mouse model harboring the RyR2 Ex3-del mutant.
As shown in Fig. 1, the 105-bp exon-3 sequence and the intron
sequences (15-bp on both sides) that flank exon-3 were removed
from an RyR2 genomic DNA fragment. This modified RyR2
DNA fragment was then used to construct the Ex3-del knock-in
plasmid (Fig. 1A,B). Mouse embryonic stem (ES) cells were
transfected with the Ex3-del knock-in plasmid. Southern blot
screening of transfected ES cells identified 8 positive recombi-
nant ES cell clones (Fig. 1C). One of these positive ES cell
clones was then used to produce heterozygous RyR2 Ex3-del
mutant mice (Ex3-del+/2) (Fig. 1D). Interestingly, while
heterozygous Ex3-del mice survived and showed no obvious
gross defects, no homozygous RyR2 Ex3-del mice were ever
detected, suggesting that homozygous RyR2 exon-3 deletion is
embryonically lethal in mice.
To confirm the absence of exon-3 in the Ex3-del+/2 mice at the
mRNA level, we isolatedmRNAs from the wild type (WT) and Ex3-
del+/2mouse hearts and generated cDNA fragments covering exon-
3 viaRT-PCR. Sequencing analysis of these cDNA fragments shows
that the RyR2 exon-3 sequence in the Ex3-del+/2 mouse heart has
indeed been deleted (Fig. 2).
Heterozygous RyR2 Ex3-del mutant mice show no stress-
induced ventricular tachyarrhythmias
Deletion of exon-3 in RyR2 has been associated with CPVT
in humans. To assess whether Ex3-del+/2 mutant mice are
susceptible to stress-induced ventricular tachyarrhythmias (VTs),
we monitored the ECG of these mice before and after the
injection of pharmacological triggers (caffeine/epinephrine). We
have previously shown that these triggers readily induced VTs
in the CPVT-linked RyR2 R4496C+/2 mutant mice [24].
Unexpectedly, we found that caffeine and epinephrine did not
induce VTs in either RyR2 Ex3-del+/2 mutant mice (n = 14) or
their WT littermates (n = 16) at 1.5–3 months of age (Fig. 3). To
assess whether their susceptibility to CPVT is age-dependent,
we performed the same caffeine/epinephrine stress tests on mice
at 3–5 months of age (5 WT and 10 Ex3-del+/2 mice) and 8–
Exon-3 Deletion Reduces RyR2 Expression in Mice
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9 months of age (8 Ex3-del+/2 mice). Similarly, we found that
none of these older WT or Ex3-del+/2 mutant mice showed
stress-induced VTs. Thus, CPVT susceptibility in Ex3-del+/2
mutant mice is unlikely to be age-dependent.
Depolarization-induced Ca2+ transients in WT and
heterozygous Ex3-del mutant cardiomyocytes
To determine whether Ex3-del+/2 mutant cardiomyocytes
exhibit altered excitation-contraction coupling, we analyzed the
amplitude and dynamics of Ca2+ release evoked by depolarization
in cardiac myocytes isolated from RyR2 WT and Ex3-del+/2
mutant mice using confocal line-scan Ca2+ imaging. As shown in
Fig. 4, there was no significant difference (P= 0.472) in the Ca2+
transient amplitude (DF/F0; WT: 3.3260.17 vs. Ex3-del+/2:
3.2960.14) between RyR2 WT (n=35) and Ex3-del+/2 mutant
(n = 58) ventricular myocytes. On the other hand, the time-to-peak
(WT: 32.560.7 ms vs. Ex3-del+/2: 36.460.5 ms, P,0.001) and
time-to-50% decay (T50; WT: 44.861.5 ms vs. Ex3-del+/2:
48.360.9 ms, P,0.05) in Ex3-del+/2 mutant cells were slightly
but significantly increased compared to those in the RyR2 WT
cells.
Heterozygous RyR2 Ex3-del mutant hearts display
markedly reduced RyR2 protein expression
The lack of CPVT phenotype in RyR2 Ex3-del+/2 mutant mice
is surprising given the impact of Ex3-del on RyR2 function in
heterologous systems and its link to CPVT and other cardiac
abnormalities in patients [11–14,18]. This lack of phenotypes
Figure 1. Generation of the RyR2 Ex3-del mutant mouse model. (A) The mouse ryr2 locus (top line), the construction of the knock-in (KI)
vector containing the deletion of the exon-3 and flanking intron sequences in the mouse ryr2 gene, the selectable markers neo (neomycin resistant
gene) and DTA (diphtheria toxin A), the FRT sites (middle line), the generation of the exon-3 deletion mutant allele, and the removal of the neo gene
via homologous recombination (bottom line) are depicted. (B) Intron and exon sequences that were deleted in the RyR2 Ex3-del mutant mice. (C)
Southern blot analysis of recombinant embryonic stem cells (WT, wild type; Het, heterozygous). (D) PCR genotyping using tail samples from WT and
Ex3-del heterozygous (Het) mice.
doi:10.1371/journal.pone.0095615.g001
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could result from poor expression of the RyR2 Ex3-del mutant
protein. To test this possibility, we performed immunoblotting
analysis to assess the level of the RyR2 protein expressed in Ex3-
del+/2 mutant and WT hearts. It should be noted that it is difficult
to distinguish the RyR2 Ex3-del mutant protein from the RyR2
WT, as there are currently no specific probes available for the
detection of the RyR2 Ex3-del mutant protein. Thus, we
examined the total RyR2 protein expressed in the WT and
mutant hearts. As shown in Fig. 5, heterozygous Ex3-del mutant
hearts (n = 4) exhibited a markedly reduced level of RyR2 protein
(5863%) as compared to WT hearts (n = 4) (P,0.001). Thus,
these data indicate that deletion of exon-3 significantly reduces the
expression of RyR2 protein in mice. Since the expression of the
normal WT RyR2 allele in the heterozygous Ex3-del mutant heart
is unlikely to be markedly altered, the reduction in RyR2
expression observed in the heterozygous Ex3-del mutant heart
would mostly result from the impaired expression of the Ex3-del
mutant allele. Hence, the absence of CPVT phenotype in RyR2
Ex3-del+/2 mutant mice may be attributable to the lack of
expression of the Ex3-del mutant RyR2 allele.
Cardiac-specific, conditional knockout of the WT RyR2
allele in heterozygous RyR2 Ex3-del mutant mice
To test the possibility that the predominant expression of the
WT allele over the mutant allele in Ex3-del+/2 mutant mice
may mask the impact of the RyR2 Ex3-del mutation, we
employed the Cre-Lox recombination technology to condition-
ally and specifically reduce the expression level of the WT
RyR2 allele in the Ex3-del+/2 mutant heart. We reasoned that
by specifically reducing the expression of the WT allele, we
might be able to reveal the impact of the Ex3-del mutation. To
this end, we bred the RyR2-floxed mice with the myosin heavy
chain (MHC)-mer-Cre-mer mice that express the tamoxifen-
inducible, MHC promoter-controlled Cre-recombinase [28–30].
Through this breeding, we obtained tamoxifen-inducible,
cardiac-specific RyR2 conditional KO mice (iRyR2flox/flox)
[28,29]. We then bred these iRyR2flox/flox mice with our RyR2
Ex3-del+/2 mutant mice to generate the iRyR2flox/Ex3-del mice.
To induce knockout of the WT RyR2 allele, we injected the
iRyR2flox/Ex3-del (n = 11) and iRyR2flox/flox (n = 13) mice with
tamoxifen. We found that the iRyR2flox/Ex3-del mice died
starting ,11 days post tamoxifen treatment. By 14 days post
tamoxifen treatment, most of the iRyR2flox/Ex3-del mice (10 out
11) had died. On the other hand, only 2 of the 13 iRyR2flox/flox
mice died 14 days post tamoxifen treatment (Fig. 6). Thus, upon
reducing the expression of the WT RyR2 allele, heterozygous
Ex3-del mutant mice displayed a higher rate of death than the
RyR2-floxed mice.
To gain some insight into the cause of death, we monitored the
ECG of iRyR2flox/Ex3-del and iRyR2flox/flox mice ,12 days post
tamoxifen treatment. We found that the basal heart rate of the
iRyR2flox/Ex3-del mice (535638 bpm) (n = 8) was significantly
reduced as compared to that of iRyR2flox/flox mice
(629613 bpm) (n = 11) (P = 0.012). We also performed caffeine/
epinephrine stress tests on these iRyR2flox/Ex3-del and iRyR2flox/flox
mice. We found that caffeine/epinephrine challenge did not
induce VTs in either the iRyR2flox/Ex3-del (n = 8) or iRyR2flox/flox
(n = 11) mice ,12 days post-tamoxifen treatment (Fig. 7). Thus,
upon reducing the expression of the WT RyR2 allele, heterozy-
gous Ex3-del mutant mice displayed bradycardia but no stress-
induced VTs.
To confirm that tamoxifen treatment did reduce RyR2
expression, we carried out immunoblotting analysis of whole
heart homogenates from iRyR2flox/flox and iRyR2flox/Ex3-del
mice before and after tamoxifen treatment. Indeed, we found
Figure 2. Deletion of exon-3 in the RyR2 mRNA from
heterozygous RyR2 Ex3-del mice. A fragment of the mouse RyR2
mRNA covering exon-3 was converted to cDNA and amplified using RT-
PCR from total RNAs isolated from wild type (WT) and heterozygous
RyR2 Ex3-del (Het) mutant mice (A). The RT-PCR products were isolated
and sequenced. The sequence of the RyR2 Ex3-del cDNA was shown (B).
Note that the exon-2 sequence is directly followed by the exon-4
sequence, i.e. the exon-3 sequence has been deleted.
doi:10.1371/journal.pone.0095615.g002
Figure 3. Heterozygous RyR2 Ex3-del mutant mice are not
susceptible to CPVT. Representative ECG recordings of wild type
(WT) (A) and RyR2 Ex3-del+/2 mutant (B) mice (1.5–3 months of age)
before (top) and after (bottom) the injection of epinephrine (1.6 mg/kg)
and caffeine (120 mg/kg). Note that no VTs were detected in either WT
(n = 16) or mutant (n = 14) mice during the 30-min period of ECG
recording after the injection of the triggers.
doi:10.1371/journal.pone.0095615.g003
Exon-3 Deletion Reduces RyR2 Expression in Mice
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that the expression level of RyR2 in iRyR2flox/flox mouse hearts
was significantly reduced to 37612% of (n = 6, P,0.001)
,12 days post tamoxifen treatment (as compared to the level
before treatment) (Fig. 8). Similarly, the expression level of
RyR2 in iRyR2flox/Ex3-del mouse hearts was decreased to
3368% (n= 6, P,0.001) ,12 days post tamoxifen treatment
(as compared to the level before treatment) (Fig. 8). Taken
together, these observations support the notion that the absence
of CPVT phenotype in the RyR2 Ex3-del+/2 mutant mice is
most likely due to the predominant expression of the WT allele
as a result of the markedly reduced expression of the Ex3-del
mutant RyR2 allele.
Discussion
Of more than 150 disease-associated RyR2 mutations, exon-3
deletion (Ex3-del) is the only large genomic deletion found in the
human RYR2 gene to date [2,11–14]. Analysis of the genomic
DNA sequence reveals that exon-3 in human RYR2 is flanked by
two Alu elements. Recombination between these two Alu elements
due to DNA polymerase slippage during chromosomal replication
results in a deletion of 1.1 kb genomic DNA sequence
encompassing exon-3 [11]. Similar genomic deletions around
exon-3 have been detected in a number of unrelated families,
suggesting that the area around exon-3 of the human RYR2 gene is
highly susceptible to Alu-mediated genomic rearrangements [11–
14]. These findings also suggest that the deletion of exon-3 in
human RyR2 may represent a common genetic defect and a
significant cause of RyR2-associated cardiac abnormalities.
Given its relative high prevalence and potential importance in
the pathogenesis of cardiac arrhythmias and cardiomyopathies,
we have attempted to generate a mouse model for the human
RyR2 exon-3 deletion. To this end, we produced a mouse line
in which the entire exon-3 in mouse RyR2 plus a 15-bp intron
sequence on both sides of exon-3 were deleted using the knock-
in approach. To our surprise and unlike that seen in patients
with RyR2 exon-3 deletion, heterozygous Ex3-del mutant mice
are not susceptible to stress-induced cardiac arrhythmias. No
homozygous Ex3-del mice were born. Immunoblotting analysis
revealed that the expression level of RyR2 protein in
heterozygous Ex3-del mouse hearts was reduced to 58% of
that in WT hearts. This level (58%) represents the total RyR2
protein expression (i.e. WT and mutant proteins together). The
dramatic reduction in RyR2 protein expression observed in
heterozygous Ex3-del mutant hearts likely resulted from
impaired expression of the Ex3-del mutant RyR2 allele as a
consequence of the exon-3 deletion. In line with this view, we
found that conditionally and specifically knocking-out only the
WT RyR2 allele in the heterozygous Ex3-del mutant heart
through the Cre-Lox recombination approach resulted in a
Figure 4. Depolarization-induced Ca2+ transients in WT and
heterozygous RyR2 Ex3-del mutant cardiomyocytes. Ventricular
myocytes isolated from RyR2 WT and Ex3-del+/2 mutant hearts were
loaded with Rhod-2-AM and perfused with 2 mM extracellular Ca2+ in
KRH solution and paced at 3Hz. Ca2+ transients were monitored by line-
scan confocal Ca2+ imaging. Representative images/traces of WT (A) and
Ex3-del+/2 mutant (B) cardiomyocytes, and average data of the
amplitude (C), time to peak (D), and time to 50% decay (E) of Ca2+
transients in WT and Ex3-del+/2mutant cells are shown. Data shown are
mean 6 SEM from 35 WT and 58 mutant cells (**P,0.001; *P,0.05).
doi:10.1371/journal.pone.0095615.g004
Figure 5. Reduced RyR2 protein expression in heterozygous
RyR2 Ex3-del mutant hearts. (A) Whole heart homogenates were
prepared from wild type (WT) (n = 4) and RyR2 Ex3-del2/2 mutant
(n = 4) mice (2–3 months) and used for immunoblotting analysis using
antibodies against RyR2 or b-actin. (B) The expression of RyR2 in the
Ex3-del hearts was significantly reduced (5863%) as compared to that
in WT hearts (*P,0.001).
doi:10.1371/journal.pone.0095615.g005
Figure 6. Cardiac-specific, conditional knockout of the WT
RyR2 allele in heterozygous RyR2 Ex3-del mutant mice results
in early death. iRyR2flox/flox (n = 13, black circles) and iRyR2flox/Ex3-del
(n = 11, white circles) mice were injected with tamoxifen (75 mg/kg/
day) for 3 consecutive days. The percentage of live mice (survival rate)
on day 6–14 post tamoxifen treatment is shown.
doi:10.1371/journal.pone.0095615.g006
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dramatically reduced level of RyR2 expression. These observa-
tions indicate that a large portion of the RyR2 protein
expressed in heterozygous Ex3-del mutant hearts is contributed
by the expression of the WT allele. In other words, only a small
amount of Ex3-del mutant protein is expressed in heterozygous
Ex3-del mutant hearts. Based on these observations, we propose
that the lack of CPVT and other phenotypes in heterozygous
RyR2 Ex3-del mutant mice is likely due to the predominant
expression of the WT RyR2 allele because of a dramatically
reduced expression level of the Ex3-del mutant protein. In this
regard, the expression of RyR2 in heterozygous Ex3-del mutant
mice may resemble that in heterozygous RyR2 KO mice. It is
important to know that there are no obvious structural and
functional abnormalities detected in heterozygous RyR2 KO
mice, while homozygous RyR2 KO is embryonically lethal [36].
Similarly, homozygous RyR2 exon-3 deletion is also embryon-
ically lethal, most likely due to the markedly reduced expression
level of the Ex3-del mutant protein and the mutation itself.
Individuals heterozygous for the RyR2 exon-3 deletion
display a number of clinical phenotypes. These include
sinoatrial node dysfunction, atrial arrhythmias, AV block, atrial
standstill, bradycardia, dilated cardiomyopathy, or left ventric-
ular non-compaction in addition to CPVT. However, none of
these phenotypes were observed in heterozygous RyR2 Ex3-del
mutant mice. The predominant expression of the WT RyR2
allele over the Ex3-del mutant allele may mask the impact of
the mutant. In support of this view, we found that upon
specifically reducing the expression of the WT RyR2 allele,
heterozygous Ex3-del mutant mice exhibited bradycardia and
death. The exact cause of bradycardia and death in iRyR2flox/
Ex3-del mice after tamoxifen treatment is, however, unclear.
Bround et al. [28] have recently shown that tamoxifen-induced,
cardiac specific ablation of RyR2 is sufficient to cause
bradycardia and death in mice. Since Ex3-del markedly reduces
the protein expression of RyR2, removal of the WT RyR2
allele in iRyR2flox/Ex3-del mice after tamoxifen treatment would
further decrease the already reduced level of RyR2 protein
expression in iRyR2flox/Ex3-del mice. Such a profound reduction
in RyR2 protein expression itself would lead to bradycardia and
death [28]. Because of the markedly reduced expression of the
Ex3-del mutant protein, the functional impact of Ex3-del on the
RyR2 channel is unlikely to contribute significantly to brady-
cardia and death observed in iRyR2flox/Ex3-del mice. Further
investigations are clearly needed to understand how deletion of
exon-3 in RyR2 causes bradycardia and sudden death in
humans.
Figure 7. Heterozygous RyR2 Ex3-del mutant mice with cardiac
specific, conditional KO of the WT RyR2 allele exhibit
bradycardia, but no CPVT. iRyR2flox/flox (n = 11) and iRyR2flox/Ex3-del
(n = 8) mice were treated with tamoxifen. ECG recording was performed
12 days post tamoxifen treatment to determine their basal heart rates
(before epinephrine/caffeine challenge) (A) and their susceptibility to
CPVT (B, C). Representative ECG recordings of the tamoxifen-treated
iRyR2flox/flox mice (B) and the tamoxifen-treated iRyR2flox/Ex3-del mice (C)
before (top panel) and after (bottom panel) the injection of epinephrine
(1.6 mg/kg) and caffeine (120 mg/kg). Note that no VTs were detected
in either the tamoxifen-treated iRyR2flox/flox mice (B) or the tamoxifen-
treated iRyR2flox/Ex3-del mice during the 30-min period of ECG recording
after the injection of the triggers (*P,0.05).
doi:10.1371/journal.pone.0095615.g007
Figure 8. Cardiac specific, conditional knockout of the WT
RyR2 allele results in markedly reduced RyR2 expression.Whole
heart homogenates were prepared from iRyR2flox/flox (A) and iRyR2flox/
Ex3-del (B) mice before and after tamoxifen treatment, and used for
immunoblotting analysis using antibodies against RyR2 or b-actin. Note
that the expression of RyR2 in iRyR2flox/flox hearts (n = 6) or iRyR2flox/Ex3-
del hearts (n = 6) was significantly reduced 12 days post tamoxifen
treatment (*P,0.001).
doi:10.1371/journal.pone.0095615.g008
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The exact mechanism by which deletion of exon-3 affects the
expression of the RyR2 protein has yet to be determined.
Although deletion of exon-3 is rescued by b-strand switching in
the context of the NH2-terminal domains of RyR2, it is unclear
whether exon-3 deletion affects the stability and turnover of the
full-length RyR2 protein in vivo. Furthermore, there may be
species differences. The impact of exon-3 deletion on the synthesis
and/or degradation of the RyR2 protein in mice and humans may
be different. Further studies will be needed to understand how
exon-3 deletion leads to a marked reduction in RyR2 expression.
An interesting and important question is whether the deletion of
exon-3 affects the expression of the human RyR2 protein in
patients. Among the mutant carriers, the clinical phenotypes and
severities of patients with the RyR2 exon-3 deletion appear to be
variable. For instance, some patients exhibit dilated cardiomyop-
athies, while others show no consistent structural abnormalities.
Further, some patients were characterized with severe sinus
bradycardia and atrioventricular block, atrial fibrillation, while
others display only bradycardia [11–14]. It is possible that variable
levels of expression of the RyR2 Ex3-del mutant allele may be
attributable, in part, to the various clinical phenotypes and
variable severities observed in patients with the RyR2 exon-3
deletion. Analysis of the expression level of the RyR2 protein in
heart samples of patients with Ex3-del will be required to test this
possibility.
A large number of RyR2 mutations have been associated with
cardiac arrhythmias and cardiomyopathies [3–5]. The impact of
these mutations on the expression of the RyR2 protein is largely
unknown. Our present study demonstrates that RyR2 mutations,
especially those large genomic rearrangements, may have signif-
icant impact on protein expression, thus affecting the ramification
of the disease mutations.
Author Contributions
Conceived and designed the experiments: YL RW BS JC JDJ AG SRWC.
Performed the experiments: YL RW BS TM YMMJB. Analyzed the data:
YL BS TM JZ SRWC. Wrote the paper: YL RW JDJ SRWC.
References
1. Bers DM (2002) Cardiac excitation-contraction coupling. Nature 415: 198–205.
2. Priori SG, Chen SR (2011) Inherited dysfunction of sarcoplasmic reticulum
Ca2+ handling and arrhythmogenesis. Circ Res 108: 871–883.
3. George CH, Jundi H, Thomas NL, Fry DL, Lai FA (2007) Ryanodine receptors
and ventricular arrhythmias: Emerging trends in mutations, mechanisms and
therapies. J Mol Cell Cardiol 42: 34–50.
4. Dulhunty AF, Beard NA, Hanna AD (2012) Regulation and dysregulation of
cardiac ryanodine receptor (RyR2) open probability during diastole in health
and disease. J Gen Physiol 140: 87–92.
5. Venetucci L, Denegri M, Napolitano C, Priori SG (2012) Inherited calcium
channelopathies in the pathophysiology of arrhythmias. Nat Rev Cardiol 9:
561–575.
6. Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, et al. (2001)
Identification of mutations in the cardiac ryanodine receptor gene in families
affected with arrhythmogenic right ventricular cardiomyopathy type 2
(ARVD2). Hum Mol Genet 10: 189–94.
7. Bauce B, Rampazzo A, Basso C, Bagattin A, Daliento L, et al. (2002) Screening
for ryanodine receptor type 2 mutations in families with effort-induced
polymorphic ventricular arrhythmias and sudden death: Early diagnosis of
asymptomatic carriers. J Am Coll Cardiol 40: 341–349.
8. Tester DJ, Spoon DB, Valdivia HH, Makielski JC, Ackerman MJ (2004)
Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor
in sudden unexplained death: A molecular autopsy of 49 medical examiner/
coroner’s cases. Mayo Clin Proc 79: 1380–1384.
9. d’Amati G, Bagattin A, Bauce B, Rampazzo A, Autore C, et al. (2005) Juvenile
sudden death in a family with polymorphic ventricular arrhythmias caused by a
novel RyR2 gene mutation: Evidence of specific morphological substrates. Hum
Pathol 36: 761–767.
10. Nishio H, Iwata M, Suzuki K (2006) Postmortem molecular screening for
cardiac ryanodine receptor type 2 mutations in sudden unexplained death:
R420W mutated case with characteristics of status thymico-lymphatics. Circ J
70: 1402–1406.
11. Bhuiyan ZA, van den Berg MP, van Tintelen JP, Bink-Boelkens MT, Wiesfeld
AC, et al. (2007) Expanding spectrum of human RYR2-related disease: New
electrocardiographic, structural, and genetic features. Circulation 116: 1569–
1576.
12. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, Hofman N, Bikker H, et al.
(2009) The RYR2-encoded ryanodine receptor/calcium release channel in
patients diagnosed previously with either catecholaminergic polymorphic
ventricular tachycardia or genotype negative, exercise-induced long QT
syndrome: A comprehensive open reading frame mutational analysis. J Am
Coll Cardiol 54: 2065–2074.
13. Marjamaa A, Laitinen-Forsblom P, Lahtinen AM, Viitasalo M, Toivonen L, et
al. (2009) Search for cardiac calcium cycling gene mutations in familial
ventricular arrhythmias resembling catecholaminergic polymorphic ventricular
tachycardia. BMC Med Genet 10: 12.
14. Ohno S, Omura M, Kawamura M, Kimura H, Itoh H, et al. (2014) Exon 3
deletion of RYR2 encoding cardiac ryanodine receptor is associated with left
ventricular non-compaction. Europace. 2014 Jan 6. [Epub ahead of print].
15. Tung CC, Lobo PA, Kimlicka L, Van Petegem F (2010) The amino-terminal
disease hotspot of ryanodine receptors forms a cytoplasmic vestibule. Nature
468: 585–588.
16. Lobo PA, Kimlicka L, Tung CC, Van Petegem F (2011) The deletion of exon 3
in the cardiac ryanodine receptor is rescued by beta strand switching. Structure
19: 790–798.
17. Amador FJ, Kimlicka L, Stathopulos PB, Gasmi-Seabrook GM, Maclennan
DH, et al. (2013) Type 2 ryanodine receptor domain A contains a unique and
dynamic alpha-helix that transitions to a beta-strand in a mutant linked with a
heritable cardiomyopathy. J Mol Biol 425: 4034–4046.
18. Tang Y, Tian X, Wang R, Fill M, Chen SR (2012) Abnormal termination of
Ca2+ release is a common defect of RyR2 mutations associated with
cardiomyopathies. Circ Res 110: 968–977.
19. Cerrone M, Colombi B, Santoro M, di Barletta MR, Scelsi M, et al. (2005)
Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse
model carrier of a mutation in the cardiac ryanodine receptor. Circ Res 96: e77–
82.
20. Kannankeril PJ, Mitchell BM, Goonasekera SA, Chelu MG, Zhang W, et al.
(2006) Mice with the R176Q cardiac ryanodine receptor mutation exhibit
catecholamine-induced ventricular tachycardia and cardiomyopathy. Proc Natl
Acad Sci U S A 103: 12179–12184.
21. Goddard CA, Ghais NS, Zhang Y, Williams AJ, Colledge WH, et al. (2008)
Physiological consequences of the P2328S mutation in the ryanodine receptor
(RyR2) gene in genetically modified murine hearts. Acta Physiol (Oxf) 194: 123–
140.
22. Lehnart SE, Mongillo M, Bellinger A, Lindegger N, Chen BX, et al. (2008)
Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden
cardiac death in mice. J Clin Invest 118: 2230–2245.
23. Uchinoumi H, Yano M, Suetomi T, Ono M, Xu X, et al. (2010)
Catecholaminergic polymorphic ventricular tachycardia is caused by muta-
tion-linked defective conformational regulation of the ryanodine receptor. Circ
Res 106: 1413–1424.
24. Zhou Q, Xiao J, Jiang D, Wang R, Vembaiyan K, et al. (2011) Carvedilol and
its new analogs suppress arrhythmogenic store overload-induced Ca2+ release.
Nat Med 17: 1003–1009.
25. Shan J, Xie W, Betzenhauser M, Reiken S, Chen BX, et al. (2012) Calcium leak
through ryanodine receptors leads to atrial fibrillation in 3 mouse models of
catecholaminergic polymorphic ventricular tachycardia. Circ Res 111: 708–717.
26. Loaiza R, Benkusky NA, Powers PP, Hacker T, Noujaim S, et al. (2013)
Heterogeneity of ryanodine receptor dysfunction in a mouse model of
catecholaminergic polymorphic ventricular tachycardia. Circ Res 112: 298–308.
27. Yang HT, Tweedie D, Wang S, Guia A, Vinogradova T, et al. (2002) The
ryanodine receptor modulates the spontaneous beating rate of cardiomyocytes
during development. Proc Natl Acad Sci U S A 99: 9225–930.
28. Bround MJ, Asghari P, Wambolt RB, Bohunek L, Smits C, et al. (2012) Cardiac
ryanodine receptors control heart rate and rhythmicity in adult mice. Cardiovasc
Res 96: 372–380.
29. Bround MJ, Wambolt R, Luciani DS, Kulpa JE, Rodrigues B, et al. (2013)
Cardiomyocyte ATP production, metabolic flexibility, and survival require
calcium flux through cardiac ryanodine receptors in vivo. J Biol Chem 288:
18975–18986.
30. Sohal DS, Nghiem M, Crackower MA, Witt SA, Kimball TR, et al. (2001)
Temporally regulated and tissue-specific gene manipulations in the adult and
embryonic heart using a tamoxifen-inducible cre protein. Circ Res 89: 20–25.
31. Xiao B, Jiang MT, Zhao M, Yang D, Sutherland C, et al. (2005)
Characterization of a novel PKA phosphorylation site, serine-2030, reveals no
PKA hyperphosphorylation of the cardiac ryanodine receptor in canine heart
failure. Circ Res 96: 847–855.
32. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature 227: 680–65.
Exon-3 Deletion Reduces RyR2 Expression in Mice
PLOS ONE | www.plosone.org 8 April 2014 | Volume 9 | Issue 4 | e95615
33. Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins
from polyacrylamide gels to nitrocellulose sheets: Procedure and some
applications. Proc Natl Acad Sci U S A 76: 4350–434.
34. Hunt DJ, Jones PP, Wang R, Chen W, Bolstad J, et al. (2007) K201 (JTV519)
suppresses spontaneous Ca2+ release and [3H]ryanodine binding to RyR2
irrespective of FKBP12.6 association. Biochem J 404: 431–438.
35. Bai Y, Jones PP, Guo J, Zhong X, Clark RB, et al. (2013) Phospholamban
knockout breaks arrhythmogenic Ca2+ waves and suppresses catecholaminergic
polymorphic ventricular tachycardia in mice. Circ Res 113: 517–526.
36. Takeshima H, Komazaki S, Hirose K, Nishi M, Noda T, et al. (1998)
Embryonic lethality and abnormal cardiac myocytes in mice lacking ryanodine
receptor type 2. EMBO J 17: 3309–3316.
Exon-3 Deletion Reduces RyR2 Expression in Mice
PLOS ONE | www.plosone.org 9 April 2014 | Volume 9 | Issue 4 | e95615
